Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Mar;47(3):897-900.
doi: 10.1128/AAC.47.3.897-900.2003.

Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women

Demetra Kavatha  1 , Helen Giamarellou, Zoe Alexiou, Nickolas Vlachogiannis, Stavroula Pentea, Thomas Gozadinos, Garyphalia Poulakou, Agissilaos Hatzipapas, George Koratzanis
Affiliations
Clinical Trial

Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women

Demetra Kavatha et al. Antimicrob Agents Chemother. 2003 Mar.

Abstract

One hundred sixty-three women with uncomplicated acute lower urinary tract infections were included in a multicenter randomized study comparing cefpodoxime-proxetil (one 100-mg tablet twice daily) with trimethoprim-sulfamethoxazole (one double-strength tablet [160/800 mg] twice daily) for 3 days. A total of 30 women in both arms were excluded from the study for various reasons. At 4 to 7 days after the discontinuation of therapy, 62 of 63 (98.4%) cefpodoxime-proxetil recipients and 70 of 70 (100%) trimethoprim-sulfamethoxazole patients were clinically cured and demonstrated bacteriological eradication, respectively. At 28 days after treatment, 48 of 55 (87.3%) and 43 of 50 (86%) cefpodoxime-proxetil recipients as well as 51 of 60 (85%) and 42 of 50 (84%) trimethoprim-sulfamethoxazole recipients were clinically cured and demonstrated bacteriological eradication, respectively. Independently of the prescribed regimen, a significant difference (P < 0.001) in failure rates was observed only for patients with a previous history of three or more episodes of acute cystitis per year. With the exception of one patient in the trimethoprim-sulfamethoxazole arm who discontinued therapy because of gastrointestinal pain, both antimicrobials were well tolerated. In conclusion, cefpodoxime-proxetil treatment for 3 days was as safe and effective as trimethoprim-sulfamethoxazole for 3 days for the treatment of uncomplicated acute cystitis in women.

PubMed Disclaimer

References

    1. Bailey, R. R. 1993. Management of lower urinary tract infections. Drugs 45(Suppl. 3):139-144. - PubMed
    1. Brown, P. D., A. Freeman, and B. Foxman. 2002. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin. Infect. Dis. 34:1061-1066. - PubMed
    1. Committee on Safety of Medicine. 1985. Deaths associated with cotrimoxazole, ampicillin, and trimethoprim. British Society of Antimicrobial Chemotherapy. Her Majesty's Stationery Office, London, United Kingdom.
    1. Cox, C. E., J. F. Gravelin, and J. M. Luengo. 1991. Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections. Drugs 42(Suppl. 3):41-50. - PubMed
    1. Frampton, J. E., R. N. Brodgen, H. D. Langtry, and M. M. Buckley. 1992. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 44:889-917. - PubMed

MeSH terms

Substances